Guides, research, and insights from Welcome to powerpeptides.co
10 articlesThymosin Beta-4 fragment (TB-500) has been studied for tissue repair and wound healing. Here's what the research actually supports — and where it falls short.
In February 2026, the HHS Secretary announced 14 peptides would be 'unleashed.' Three months later, here's what's actually changed, what hasn&am
Third-party testing, certificates of analysis, purity thresholds, and red flags. A practical framework for evaluating research peptide vendors.
A clear-eyed overview of where peptides stand legally in the United States — compounding eligibility, 'research use only' designations, DEA scheduling, and what
KPV is a tripeptide fragment of alpha-MSH with documented anti-inflammatory properties in preclinical models. Here's what the research shows — and what the July 2026 PCA
The two most widely used growth hormone-releasing peptides in the research community — how they work, what the evidence shows, and why the PCAC previously voted against them.
GHK-Cu is one of the most extensively studied peptides in regenerative medicine — with decades of research, topical FDA-cleared products, and ongoing review for injectable compou
The FDA's Pharmacy Compounding Advisory Committee meets July 23-24, 2026 to review BPC-157, TB-500, KPV, and MOTs-C. Here's what's at stake and what to e
Why the research community combines these two peptides, what the theoretical basis is, and what the evidence actually supports about synergistic tissue repair.
Two decades of rodent data, a handful of early human studies, and a regulatory landscape in flux. Here's the evidence — and the gaps — for the most-discussed peptide i
No articles found matching your search.